Aptar Reports Fourth Quarter and Annual 2023 Results

Rhea-AI Summary

AptarGroup, Inc. (NYSE:ATR) reported strong fourth quarter operational results, with a 5% increase in sales and a 6% increase in net income. The company achieved double-digit growth in its proprietary drug delivery systems and fragrance dispensing technologies. The Pharma segment had an exceptional year with over 20% core sales growth in the fourth quarter, while the beauty dispensing solutions in fragrance also delivered double-digit core sales growth for 2023. The company's focus on cost management and operational leverage yielded margin expansion for each segment compared to the prior year. Tanda, President and CEO, expressed optimism for continued solid growth in 2024.

Insights

Financial Analyst

The reported earnings from AptarGroup, Inc. demonstrate a robust financial performance, particularly noting the 6% increase in net income and a 22% increase in adjusted EBITDA. This is indicative of effective cost management and operational efficiency, leading to margin expansion across the company's segments. The growth in proprietary drug delivery systems and fragrance dispensing technologies, with core sales growth over 20%, suggests that the company is successfully innovating and capturing market demand in these sectors. Investors should consider the potential for sustained growth, given the company's pipeline of new product launches and project opportunities.

However, the modest 2% increase in core sales, excluding currency and acquisition effects, may indicate that the overall market conditions are challenging, or that the company is facing stiff competition in areas outside its proprietary technologies. It is also essential to monitor how the company manages its SG&A expenses in relation to sales going forward, as this will be a critical factor in maintaining profitability.

Market Research Analyst

AptarGroup's performance in the pharmaceutical and beauty sectors is particularly noteworthy. The double-digit growth in these areas shows that the company is well-positioned in markets that are likely experiencing increased consumer demand. The reference to the highest number of new product launches since 2018 suggests that the company is not only growing but also innovating at a pace that is likely to keep it competitive. For stakeholders, the emphasis on proprietary pharma dosing and dispensing systems and beauty dispensing solutions, implies a strategic focus on niche markets where Aptar can leverage its technological advantages.

Given the company's focus on these high-growth areas, the industry-specific term 'adjusted EBITDA' (Earnings Before Interest, Taxes, Depreciation and Amortization) is significant because it reflects the company's operational profitability before non-cash charges and finance-related decisions. This metric's substantial growth suggests that the underlying business operations are becoming increasingly profitable, which is a positive sign for investors and stakeholders interested in the company's core financial health.

Medical Research Analyst

The reference to AptarGroup's proprietary drug delivery systems indicates a strategic emphasis on innovation within the pharmaceutical sector. The company's success in this area, with over 20% core sales growth, is likely due to a combination of technological advancements and an ability to meet stringent regulatory requirements. This aligns with a broader industry trend towards personalized medicine and advanced drug delivery mechanisms, which can offer better patient compliance and more effective treatments.

For the pharmaceutical industry, the introduction of new products and the expansion of the project pipeline are critical for sustained growth. Aptar's reported highest number of new product launches and the addition of new project opportunities to the pipeline may signal a robust R&D strategy that could lead to future market share gains. This is particularly relevant for stakeholders who are looking for companies with a strong innovation pipeline and the potential for long-term growth in the competitive pharmaceutical market.

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter operational results driven by double-digit growth of the company’s proprietary drug delivery systems and strong growth for fragrance dispensing technologies. Reported sales increased by 5% and core sales, excluding currency and acquisition effects, increased by 2%. Aptar reported net income of $62 million for the quarter, a 6% increase over the prior year.

Photo: Aptar

“I am pleased to report that we delivered strong fourth quarter and full year results. In 2023, we achieved year-over-year double-digit earnings per share growth, an increase of net income of almost 20% and a 15% increase in adjusted EBITDA. Our focus on cost management and operational leverage yielded margin expansion for each segment compared to the prior year and we also decreased selling, general and administrative (SG&A) expenses as a percentage of sales,” said Stephan B. Tanda, Aptar President and CEO, commenting on the full year results.

Tanda added, “Our Pharma segment had an exceptional year. In 2023, we had the highest number of new product launches since 2018, while adding an equal, risk-adjusted value of new project opportunities to the pipeline, which bodes well for continued, solid growth. A big driver of this success can be attributed to our proprietary pharma dosing and dispensing systems, which reported over 20% core sales growth in the fourth quarter and double-digit growth for the year. Our beauty dispensing solutions in fragrance also delivered double-digit core sales growth for 2023, rounding out a very successful year for us. Of course, there is more work to be done and we look forward to continuing the positive momentum into 2024 and beyond.”

Fourth Quarter 2023 Highlights

• Reported sales increased 5% and net income increased 6% to $62 million
• Core sales increased 2% and adjusted EBITDA increased 22% from the prior year to $179 million
• Reported earnings per share increased about 4% to $0.93 compared to $0.89 in the prior year and adjusted earnings per share increased 27% to $1.21 compared to $0.95 in the prior year (including comparable exchange rates)
• Margins continued to expand across all three segments over the prior year
• Achieved an adjusted EBITDA margin within the raised long-term target range

Annual 2023 Highlights

• Achieved annual sales of $3.5 billion, with sales growth driven evenly by favorable product mix, volume growth and pricing
• Reported sales grew 5% and core sales increased 3%
• Reported earnings per share increased 18% to $4.25 and adjusted earnings per share increased 24% to $4.78
• Reported net income increased 19% to $284 million and adjusted EBITDA increased 15% to $708 million
• Margin improvement was driven by cost management, mix of higher value products, higher productivity and lower input costs
• Operating cash flow was $575 million, up from $479 million in 2022
• Generated $263 million in free cash flow, up from $196 million in 2022

Fourth Quarter Results

For the quarter ended December 31, 2023, reported sales increased 5% to $838 million compared to $796 million in the prior year. Core sales, excluding the impact from changes in currency exchange rates and acquisitions, increased 2%.

Fourth Quarter Segment Sales Analysis (Change Over Prior Year)
	Aptar Pharma	Aptar Beauty	Aptar Closures	Total AptarGroup
Reported Sales Growth	15%	(2%)	(1%)	5%
Currency Effects (1)	(4%)	(4%)	(2%)	(3%)
Acquisitions	0%	0%	(1%)	0%
Core Sales Growth	11%	(6%)	(4%)	2%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

Aptar Pharma’s performance was driven by strong double-digit core sales growth for proprietary drug delivery systems used for emergency medicines, allergic rhinitis, central nervous system therapeutics, as well as eye care, nasal saline rinses, and nasal decongestants. The injectables division sales were basically flat after two years of strong core sales increases. Sales for elastomeric components used for biologics continued to grow in the quarter. Demand for active material science solutions declined due to non-recurring sales of Activ-Film™ used for at home COVID-19 test kits.

Aptar Beauty’s core sales declined compared to the prior year’s quarter, due to continued market softness in North America. Healthy demand continued for fragrance dispensing solutions in Europe and Latin America. Additionally, adjusted EBITDA margins continued to improve in the quarter.

Aptar Closures segment core sales declined compared with the prior year’s quarter due to the passing through of lower resin costs to our customers. Unit volumes were up in certain categories such as beverage in Europe, and personal care and home care in North America. Adjusted EBITDA margins continued to improve as a result of cost containment efforts.

Aptar reported fourth quarter earnings per share of $0.93, an increase of 4%, compared to $0.89 during the same period a year ago. Fourth quarter adjusted earnings per share, excluding restructuring charges and the unrealized gains or losses on an equity investment, were $1.21, an increase of 27%, compared to $0.95 in the prior year, including comparable exchange rates.

Annual Results

For the year ended December 31, 2023, reported sales increased 5% to $3.49 billion compared to $3.32 billion in the prior year. Core sales, excluding the impact from changes in currency exchange rates and acquisitions, increased 3%.

Annual Segment Sales Analysis (Change Over Prior Year)
	Aptar Pharma	Aptar Beauty	Aptar Closures	Total AptarGroup
Total Reported Sales Growth	12%	4%	(5)%	5%
Currency Effects (1)	(2)%	(2)%	(1)%	(2)%
Acquisitions	0%	0%	(1)%	0%
Core Sales Growth	10%	2%	(7)%	3%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

For the year ended December 31, 2023, Aptar’s reported earnings per share were $4.25, an increase of 18%, compared to $3.59 reported a year ago. Current year adjusted earnings per share, excluding restructuring charges, acquisition costs, and the unrealized gains or losses on an equity investment, were $4.78 and increased 24% from prior year adjusted earnings per share of $3.87, including comparable exchange rates. The prior year’s adjusted earnings included an effective tax rate of 27% (approximately $0.13 per share negative impact compared to the current year effective tax rate of 24%).

Outlook

Regarding Aptar’s outlook, Tanda stated, “In 2024, we intend to build on our positive momentum from the previous year and anticipate starting strong in the first quarter. We expect demand for pharma’s proprietary drug delivery systems and elastomeric components for biologics to continue to grow. We also expect our beauty and closures segments to benefit from a progressive recovery of the North American market and we anticipate continued demand for our fragrance dispensing technologies. We remain focused on reducing SG&A as a percentage of sales and reducing our fixed costs. We are looking forward to another dynamic year.”

Aptar currently expects earnings per share for the first quarter of 2024, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.10 to $1.18. This guidance is based on an effective tax rate range of 24.5% to 26.5% which compares to an effective tax rate of 25.6% on prior year adjusted earnings. The earnings per share guidance range was based on spot rates at the end of January for all currencies. Our currency exchange rate assumptions equate to an approximately $0.01 per share tailwind when compared to the prior year first quarter earnings.

Cash Dividends and Share Repurchases

As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.41 per share. The payment date is February 22, 2024, to stockholders of record as of February 1, 2024. During the fourth quarter, Aptar repurchased 81 thousand shares for $10.3 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

Open Conference Call

There will be a conference call held on Friday, February 9, 2024 at 8:00 a.m. Central Time to discuss the company’s fourth quarter and annual results for 2023. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring and acquisition costs.

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the recent events in the Middle East and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; the execution of our fixed cost reduction initiatives, including our optimization initiative; the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs (particularly resin, metal, anodization costs and energy costs); significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to successfully implement facility expansions and new facility projects; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired, including contingent consideration valuation; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; cybersecurity threats that could impact our networks and reporting systems; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; work stoppages due to labor disputes; competition, including technological advances; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

AptarGroup, Inc. Condensed Consolidated Financial Statements (Unaudited) (In Thousands, Except Per Share Data) Consolidated Statements of Income
	Three Months Ended December 31,								Year Ended December 31,
		2023				2022				2023				2022
Net Sales	$	838,480			$	795,914			$	3,487,450			$	3,322,249
Cost of Sales (exclusive of depreciation and amortization shown below)		526,227				520,297				2,224,051				2,158,411
Selling, Research & Development and Administrative		138,295				127,911				565,783				544,262
Depreciation and Amortization		64,381				58,888				248,593				233,706
Restructuring Initiatives		25,376				3,608				45,004				6,597
Operating Income		84,201				85,210				404,019				379,273
Other Income (Expense):
Interest Expense		(10,518	)			(10,159	)			(40,418	)			(40,827	)
Interest Income		2,107				671				4,373				2,700
Net Investment (Loss) Gain		(426	)			(1,026	)			1,413				(2,110	)
Equity in Results of Affiliates		712				651				2,226				467
Miscellaneous Income (Expense), net		4,553				(1,655	)			3,212				(4,799	)
Income before Income Taxes		80,629				73,692				374,825				334,704
Provision for Income Taxes		18,384				14,298				90,649				95,149
Net Income	$	62,245			$	59,394			$	284,176			$	239,555
Net Loss (Income) Attributable to Noncontrolling Interests		110				(398	)			311				(267	)
Net Income Attributable to AptarGroup, Inc.	$	62,355			$	58,996			$	284,487			$	239,288
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic	$	0.95			$	0.90			$	4.34			$	3.66
Diluted	$	0.93			$	0.89			$	4.25			$	3.59
Average Numbers of Shares Outstanding:
Basic		65,813				65,272				65,616				65,402
Diluted		67,131				66,442				66,905				66,719

AptarGroup, Inc. Condensed Consolidated Financial Statements (Unaudited) (continued) ($ In Thousands) Consolidated Balance Sheets
	December 31, 2023			December 31, 2022
ASSETS
Cash and Equivalents	$	223,643		$	141,732
Accounts and Notes Receivable, Net		677,822			676,987
Inventories		513,053			486,806
Prepaid and Other		134,761			124,766
Total Current Assets		1,549,279			1,430,291
Property, Plant and Equipment, Net		1,478,063			1,343,664
Goodwill		963,418			945,632
Other Assets		461,130			483,871
Total Assets	$	4,451,890		$	4,203,458
LIABILITIES AND STOCKHOLDERS’ EQUITY
Short-Term Obligations	$	458,220		$	122,791
Accounts Payable, Accrued and Other Liabilities		793,089			794,385
Total Current Liabilities		1,251,309			917,176
Long-Term Obligations		681,188			1,052,597
Deferred Liabilities and Other		198,095			165,481
Total Liabilities		2,130,592			2,135,254
AptarGroup, Inc. Stockholders' Equity		2,306,824			2,053,935
Noncontrolling Interests in Subsidiaries		14,474			14,269
Total Stockholders' Equity		2,321,298			2,068,204
Total Liabilities and Stockholders' Equity	$	4,451,890		$	4,203,458

AptarGroup, Inc. Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands)
	Three Months Ended December 31, 2023
	Consolidated					Aptar Pharma				Aptar Beauty				Aptar Closures				Corporate & Other				Net Interest
Net Sales	$	838,480				$	385,059			$	287,741			$	165,680			$	—			$	—
Reported net income	$	62,245
Reported income taxes		18,384
Reported income before income taxes		80,629					99,812				12,567				(5,559	)			(17,780	)			(8,411	)
Adjustments:
Restructuring initiatives		25,376					3,195				8,033				13,867				281
Net investment loss		426					—				—				—				426
Transaction costs related to acquisitions		225					—				225				—				—
Adjusted earnings before income taxes		106,656					103,007				20,825				8,308				(17,073	)			(8,411	)
Interest expense		10,518																					10,518
Interest income		(2,107	)																				(2,107	)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		115,067					103,007				20,825				8,308				(17,073	)			—
Depreciation and amortization		64,381					28,118				21,516				13,998				749
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	179,448				$	131,125			$	42,341			$	22,306			$	(16,324	)		$	—
Reported net income margins (Reported net income / Reported Net Sales)		7.4	%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		21.4	%				34.1	%			14.7	%			13.5	%

	Three Months Ended December 31, 2022
	Consolidated					Aptar Pharma				Aptar Beauty				Aptar Closures				Corporate & Other				Net Interest
Net Sales	$	795,914				$	335,166			$	292,742			$	168,006			$	—			$	—
Reported net income	$	59,394
Reported income taxes		14,298
Reported income before income taxes		73,692					83,773				16,654				2,891				(20,138	)			(9,488	)
Adjustments:
Restructuring initiatives		3,608					—				2,765				843				—
Net investment loss		1,026					—				—				—				1,026
Adjusted earnings before income taxes		78,326					83,773				19,419				3,734				(19,112	)			(9,488	)
Interest expense		10,159																					10,159
Interest income		(671	)																				(671	)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		87,814					83,773				19,419				3,734				(19,112	)			—
Depreciation and amortization		58,888					24,056				20,125				13,355				1,352
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	146,702				$	107,829			$	39,544			$	17,089			$	(17,760	)		$	—
Reported net income margins (Reported net income / Reported Net Sales)		7.5	%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		18.4	%				32.2	%			13.5	%			10.2	%

AptarGroup, Inc. Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands)
	Year Ended December 31, 2023
	Consolidated					Aptar Pharma				Aptar Beauty				Aptar Closures				Corporate & Other				Net Interest
Net Sales	$	3,487,450				$	1,520,993			$	1,267,697			$	698,760			$	—			$	—
Reported net income	$	284,176
Reported income taxes		90,649
Reported income before income taxes		374,825					388,415				59,210				33,615				(70,370	)			(36,045	)
Adjustments:
Restructuring initiatives		45,004					4,852				20,683				17,927				1,542
Net investment gain		(1,413	)				—				—				—				(1,413	)
Realized gain on investments included in net investment gain above		4,188					—				—				—				4,188
Transaction costs related to acquisitions		480					—				424				56				—
Adjusted earnings before income taxes		423,084					393,267				80,317				51,598				(66,053	)			(36,045	)
Interest expense		40,418																					40,418
Interest income		(4,373	)																				(4,373	)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		459,129					393,267				80,317				51,598				(66,053	)			—
Depreciation and amortization		248,593					109,366				83,399				52,095				3,733
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	707,722				$	502,633			$	163,716			$	103,693			$	(62,320	)		$	—
Reported net income margins (Reported net income / Reported Net Sales)		8.1	%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		20.3	%				33.0	%			12.9	%			14.8	%

	Year Ended December 31, 2022
	Consolidated					Aptar Pharma				Aptar Beauty				Aptar Closures				Corporate & Other				Net Interest
Net Sales	$	3,322,249				$	1,361,256			$	1,222,535			$	738,458			$	—			$	—
Reported net income	$	239,555
Reported income taxes		95,149
Reported income before income taxes		334,704					346,995				65,850				32,185				(72,199	)			(38,127	)
Adjustments:
Restructuring initiatives		6,597					—				5,539				1,058				—
Net investment loss		2,110					—				—				—				2,110
Realized gain on investments included in net investment loss above		1,213					—				—				—				1,213
Transaction costs related to acquisitions		231					231				—				—				—
Adjusted earnings before income taxes		344,855					347,226				71,389				33,243				(68,876	)			(38,127	)
Interest expense		40,827																					40,827
Interest income		(2,700	)																				(2,700	)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		382,982					347,226				71,389				33,243				(68,876	)			—
Depreciation and amortization		233,706					94,396				80,498				52,866				5,946				—
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	616,688				$	441,622			$	151,887			$	86,109			$	(62,930	)		$	—
Reported net income margins (Reported net income / Reported Net Sales)		7.2	%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		18.6	%				32.4	%			12.4	%			11.7	%

AptarGroup, Inc. Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) (In Thousands, Except Per Share Data)
	Three Months Ended December 31,							Year Ended December 31,
		2023			2022				2023				2022
Income before Income Taxes	$	80,629		$	73,692			$	374,825			$	334,704
Adjustments:
Restructuring initiatives		25,376			3,608				45,004				6,597
Net investment loss (gain)		426			1,026				(1,413	)			2,110
Realized gain on investments included in net investment loss (gain) above		—			—				4,188				1,213
Transaction costs related to acquisitions		225			—				480				231
Foreign currency effects (1)					2,877								8,204
Adjusted Earnings before Income Taxes	$	106,656		$	81,203			$	423,084			$	353,059
Provision for Income Taxes	$	18,384		$	14,298			$	90,649			$	95,149
Adjustments:
Net effect of items included in the Provision for Income Taxes (2)		—			1,350				—				(5,850	)
Restructuring initiatives		6,769			1,023				11,939				1,818
Net investment loss (gain)		104			251				(346	)			517
Realized gain on investments included in net investment loss (gain) above		—			—				1,026				297
Transaction costs related to acquisitions		56			—				121				57
Foreign currency effects (1)					558								2,332
Adjusted Provision for Income Taxes	$	25,313		$	17,480			$	103,389			$	94,320
Net (Income) Loss Attributable to Noncontrolling Interests	$	110		$	(398	)		$	311			$	(267	)
Net Income Attributable to AptarGroup, Inc.	$	62,355		$	58,996			$	284,487			$	239,288
Adjustments:
Net effect of items included in the Provision for Income Taxes (2)		—			(1,350	)			—				5,850
Restructuring initiatives		18,607			2,585				33,065				4,779
Net investment loss (gain)		322			775				(1,067	)			1,593
Realized gain on investments included in net investment loss (gain) above		—			—				3,162				916
Transaction costs related to acquisitions		169			—				359				174
Foreign currency effects (1)					2,319								5,872
Adjusted Net Income Attributable to AptarGroup, Inc.	$	81,453		$	63,325			$	320,006			$	258,472
Average Number of Diluted Shares Outstanding		67,131			66,442				66,905				66,719
Net Income Attributable to AptarGroup, Inc. Per Diluted Share	$	0.93		$	0.89			$	4.25			$	3.59
Adjustments:
Net effect of items included in the Provision for Income Taxes (2)		—			(0.02	)			—				0.09
Restructuring initiatives		0.28			0.04				0.49				0.07
Net investment loss (gain)		—			0.01				(0.02	)			0.03
Realized gain on investments included in net investment loss (gain) above		—			—				0.05				0.01
Transaction costs related to acquisitions		—			—				0.01				—
Foreign currency effects (1)					0.03								0.08
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share	$	1.21		$	0.95			$	4.78			$	3.87
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.
(2) Items included in the Provision for Income Taxes reflects a tax expense related to a legal entity reorganization.

AptarGroup, Inc. Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) (In Thousands)
	Three Months Ended December 31,								Year Ended December 31,
		2023				2022				2023				2022
Net Cash Provided by Operations	$	219,637			$	172,268			$	575,239			$	478,617
Capital Expenditures		(81,143	)			(84,296	)			(312,342	)			(310,427	)
Proceeds from Government Grants		—				10,737				—				27,795
Free Cash Flow	$	138,494			$	98,709			$	262,897			$	195,985

AptarGroup, Inc. Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) (In Thousands, Except Per Share Data)
	Three Months Ending March 31,
	Expected 2024			2023
Income before Income Taxes			$	73,269
Adjustments:
Restructuring initiatives				11,524
Net investment gain				(188	)
Transaction costs related to acquisitions				255
Foreign currency effects (1)				1,304
Adjusted Earnings before Income Taxes			$	86,164
Provision for Income Taxes			$	18,683
Adjustments:
Restructuring initiatives				3,065
Net investment gain				(46	)
Transaction costs related to acquisitions				65
Foreign currency effects (1)				333
Adjusted Provision for Income Taxes			$	22,100
Net Loss Attributable to Noncontrolling Interests			$	178
Net Income Attributable to AptarGroup, Inc.			$	54,764
Adjustments:
Restructuring initiatives				8,459
Net investment gain				(142	)
Transaction costs related to acquisitions				190
Foreign currency effects (1)				971
Adjusted Net Income Attributable to AptarGroup, Inc.			$	64,242
Average Number of Diluted Shares Outstanding				66,735
Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3)			$	0.82
Adjustments:
Restructuring initiatives				0.13
Net investment gain				—
Transaction costs related to acquisitions				—
Foreign currency effects (1)				0.01
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2)	$1.10 - $1.18		$	0.96
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using spot rates as of January 31, 2024 for all applicable foreign currency exchange rates.
(2) AptarGroup’s expected earnings per share range for the first quarter of 2024, excluding any restructuring expenses, acquisition costs and changes in fair value of equity investments, is based on an effective tax rate range of 24.5% to 26.5%. This tax rate range compares to our first quarter of 2023 effective tax rate of 25.5% on reported earnings per share and 25.6% on adjusted earnings per share.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240208100452/en/

Investor Relations Contact:

Mary Skafidas

mary.skafidas@aptar.com

815-479-5530

Media Contact:

Katie Reardon

katie.reardon@aptar.com

815-479-5671

Source: AptarGroup, Inc.

FAQ

What is the ticker symbol for AptarGroup, Inc.?

The ticker symbol for AptarGroup, Inc. is ATR.

What were the reported sales increase and net income increase for the fourth quarter of 2023?

The reported sales increased by 5% and net income increased by 6% to $62 million for the fourth quarter of 2023.

What was the core sales increase for the fourth quarter of 2023?

The core sales increased by 2% for the fourth quarter of 2023.

What was the adjusted EBITDA increase for the fourth quarter of 2023?

The adjusted EBITDA increased by 22% from the prior year to $179 million for the fourth quarter of 2023.

What was the percentage increase in earnings per share for the year 2023?

The company achieved year-over-year double-digit earnings per share growth in 2023.

What were the key drivers of success for AptarGroup in 2023?

The company's proprietary drug delivery systems and beauty dispensing solutions in fragrance reported double-digit core sales growth, contributing to the overall success in 2023.